Regulatory, ethical, and clinical barriers to exosome use in interventional pain medicine

Exosome-based therapies have drawn growing attention in interventional pain medicine as clinicians look for regenerative options beyond corticosteroids, radiofrequency ablation, and cell-based procedures. The early preclinical work suggests anti-inflammatory and neuromodulatory effects relevant to muskuloskeletal and spine pain. However, this promise is currently outpaced by clinical marketing. No exosome product is United States Food and Drug Administration (FDA) approved for musculoskeletal or pain indications, and all therapeutic use in the United States requires an Investigational New Drug application, Institutional Review Board oversight, and Good Manufacturing Practice (GMP) grade manufacturing. Despite this, a parallel cash-pay market has expanded, offering "361-compliant" or "minimally manipulated" exosomes for intradiscal, epidural, or joint injection, in direct conflict with FDA guidelines. This review outlines the regulatory landscape governing exosome products in the United States, Europe, and Asia; describes key manufacturing and characterization challenges that undermine consistency and potency; and examines the ethical and medico-legal issues created when unapproved biologics are marketed directly to patients. Scientific barriers remain substantial, including heterogeneous isolation techniques, unstable product profiles, unresolved dosing metrics, and limited human data. These gaps, combined with high economic barriers to GMP production, prevent exosomes from being responsibly incorporated into interventional pain practice.